Risedronic acid: new indication. No fewer symptomatic fractures in men.
D002986:Clinical Trials as Topic; D017277:Drug Approval; D012968:Etidronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D050723:Fractures, Bone / Q000517:prevention & control*; D005602:France; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy*
D012968:Etidronic Acid